SCHEMBL472132

SCHEMBL472132

C1CNCCCNCCCNCCCNC1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 4/20 0.89
SMN1; SMN2 Q16637 1/20 0.89
ALDH1A1 P00352 1/20 0.70
HIF1A Q16665 1/20 0.56
MAPT P10636 1/20 0.56
PDE4A P27815 1/20 0.56
KDR P35968 1/20 0.56
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
CYP2C9 P11712 1/20 0.33
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
ADRA2C P18825 1/20 0.31
CCR2 P41597 1/20 0.31
CXCL12 P48061 1/20 0.31
BLM P54132 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316126 1.00 CXCR4 (0.89) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
SCHEMBL623920 1.00
SCHEMBL11232630 1.00 CXCR4 (0.89) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
SCHEMBL11235838 1.00 CXCR4 (0.89) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
SCHEMBL577659 0.94 CXCR4 (1.00) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
SCHEMBL576838 0.94 CXCR4 (1.00) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
SCHEMBL3632859 0.94 CXCR4 (0.80) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
SCHEMBL22199 0.94 CXCR4 (1.00) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
SCHEMBL9947670 0.94 CXCR4 (1.00) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT
SCHEMBL8503965 0.94 CXCR4 (1.00) CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719486-A1 CONJUGATES AND USES THEREOF Full-Life Technologies UK Limited (GB) 2026-04-08 EP claimed
EP-4719498-A1 RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF Full-Life Technologies UK Limited (GB) 2026-04-08 EP claimed
WO-2025199636-A1 TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF MCMASTER UNIVERSITY (CA) 2025-10-02 WO claimed
EP-4619411-A1 DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF Full-Life Technologies HK Limited (HK) 2025-09-24 EP claimed
CN-120129690-A Dual receptor targeted radioligands and uses thereof 辐联科技香港有限公司 2025-06-10 CN claimed
EP-4556029-A2 RADIOPHARMACEUTICAL CONJUGATE The South African Nuclear Energy Corporation Limited (ZA) 2025-05-21 EP claimed
US-20250099632-A1 CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF FULL-LIFE TECHNOLOGIES UK LIMITED (GB) 2025-03-27 US claimed
CN-119565397-A High-flux high-chemical-resistance composite nanofiltration membrane and preparation method and application thereof 万华化学集团股份有限公司 2025-03-07 CN claimed
US-20250026739-A1 COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF FULL-LIFE TECHNOLOGIES HK LIMITED (CN) 2025-01-23 US claimed
EP-4479040-A1 COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF Full-Life Technologies HK Limited (HK) 2024-12-25 EP claimed
US-20120213698-A1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES RIGSHOSPITALET (DK) 2012-08-23 US claimed
EP-2399938-A2 Peptide purification by means of hard metal ion affinity chromatography Novo Nordisk A/S (DK) 2011-12-28 EP claimed
US-20090143529-A1 Peptide purification by means of hard metal ion affinity chromatography HEARN MILTON THOMAS WILLIAM 2009-06-04 US claimed
US-7452845-B2 Mesoporous organic-inorganic hybrid materials for separating gases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2008-11-18 US claimed
EP-1370563-B1 MESOPOROUS ORGANIC-INORGANIC HYBRID MATERIALS FOR SEPARATING GASES CENTRE NAT RECH SCIENT (FR) 2006-09-06 EP claimed
US-20040122250-A1 Mesoporous organic-inorganic hybrid materials for separating gases CENTRE NATIONAL DE LA RECHERCHE-SCIENTIFIQUE (FR) 2004-06-24 US claimed
EP-0325307-B1 MACROCYCLIC POLYAMINE MULTIFUNCTIONAL LUBRICATING OIL ADDITIVES EXXON RESEARCH AND ENGINEERING COMPANY (US) 1993-02-03 EP claimed
EP-0325307-A2 Macrocyclic polyamine multifunctional lubricating oil additives EXXON RESEARCH AND ENGINEERING COMPANY (US) 1989-07-26 EP claimed
EP-0113582-A2 Macrocyclic polyamine and polycyclic polyamine multifunctional lubricating oil additives EXXON RESEARCH AND ENGINEERING COMPANY (US) 1984-07-18 EP claimed
US-4001212-A EXTRACT METAL IONS FROM SOLUTION AND COMPLEX E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-01-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026739-A1 COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF NTSR1, NTSR2, NPSR1 CXCR4 447/4885SMN1; SMN2 1239/4885ALDH1A1 3833/4885
US-20040122250-A1 Mesoporous organic-inorganic hybrid materials for separating gases SCO2, IPO9, IPO4 CXCR4 1677/4885SMN1; SMN2 2963/4885ALDH1A1 4090/4885
US-20250099632-A1 CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF ASGR1, GNRHR, SCTR CXCR4 641/4885SMN1; SMN2 3813/4885ALDH1A1 3790/4885
US-20090143529-A1 Peptide purification by means of hard metal ion affinity chromatography MAX, PTMS, SLC7A1 CXCR4 1801/4885SMN1; SMN2 3612/4885ALDH1A1 4834/4885
US-20120213698-A1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES LIPG, NPC1L1, CD47 CXCR4 790/4885SMN1; SMN2 4425/4885ALDH1A1 4468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.